skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Saxagliptin for type 2 diabetes

Review

(2469) Views  (772) Full article downloads

Authors: Antonio R Chacra, MD

Published Date September 2010 Volume 2010:3 Pages 325 - 335
DOI: http://dx.doi.org/10.2147/DMSO.S12241

Antonio R Chacra, MD
Diabetes Center, Federal University of São Paulo, Brazil

Abstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking DPP-4, saxagliptin increases and prolongs the effects of incretins, a group of peptide hormones released by intestinal cells after meals, which stimulate glucose-dependent insulin secretion to lower blood glucose. In controlled clinical trials, saxagliptin administered as monotherapy or in combination with metformin, glyburide, or a thiazolidinedione improved glycemic control in a clinically significant manner, reflected by significant decreases in glycated hemoglobin (monotherapy, -0.5%; add-on to metformin, thiazolidinedione, or sulfonylurea, -0.6% to 0.9%; initial combination with metformin, -2.5%), fasting plasma glucose, and postprandial glucose compared with controls. Additionally, saxagliptin improved β-cell function, reflected as increases in homeostasis model assessment (HOMA)-2β. Saxagliptin was generally well tolerated; it did not increase hypoglycemia compared with controls, and was weight neutral. A meta-analysis of Phase II and III trials showed that saxagliptin did not increase the risk of major cardiovascular events. Professional organizations have updated their guidelines for T2D to include a DPP-4 inhibitor as an early treatment option—either as initial therapy in combination with metformin, or as add-on therapy for patients whose glycemia is inadequately controlled by a single oral antidiabetic drug.

Keywords: saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, type 2 diabetes






Readers of this article also read:

Alogliptin: a new addition to the class of DPP-4 inhibitors
CTLA-4 blockade: therapeutic potential in cancer treatments
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
Profile of ipilimumab and its role in the treatment of metastatic melanoma
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
Targeted agents for the treatment of metastatic melanoma
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio